Spots Global Cancer Trial Database for Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors
Official Title: A Combination Phase I Open Label Dose Escalation Study of Concomitant Administration of BIBW 2992 With BIBF 1120 in Patients With Advanced Solid Tumors
Study ID: NCT00730821
Conditions
Study Description
Brief Summary: The primary objective of this trial is to determine the MTD of the combination of BIBW 2992/BIBF 1120 therapy administered concomitantly in a 28-day cycle schedule. Secondary objectives are the collection of antitumor efficacy data, the determination of pharmacokinetic parameters of BIBF 1120 and BIBW 2992, and if data allow the determination of the pharmacokinetic influence of BIBW 2992 on BIBF 1120 and vice versa.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
1239.1.3 Boehringer Ingelheim Investigational Site, Scottsdale, Arizona, United States
1239.1.1 Boehringer Ingelheim Investigational Site, Tampa, Florida, United States
1239.1.2 Boehringer Ingelheim Investigational Site, Detroit, Michigan, United States
1239.1.4 Boehringer Ingelheim Investigational Site, Omaha, Nebraska, United States
Contact Details
Name: Boehringer Ingelheim
Affiliation: Boehringer Ingelheim
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
